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Abstract Much attention has recently been devoted to the
life and behaviour of pharmaceuticals in the water cycle. In
this study the behaviour of several pharmaceutical products
in different therapeutic categories (analgesics and anti-
inflammatory drugs, lipid regulators, antibiotics, etc.) was
monitored during treatment of wastewater in a laboratory-
scale membrane bioreactor (MBR). The results were
compared with removal in a conventional activated-sludge
(CAS) process in a wastewater-treatment facility. The
performance of an MBR was monitored for approximately
two months to investigate the long-term operational
stability of the system and possible effects of solids
retention time on the efficiency of removal of target
compounds. Pharmaceuticals were, in general, removed to
a greater extent by the MBR integrated system than during
the CAS process. For most of the compounds investigated
the performance of MBR treatment was better (removal
rates >80%) and effluent concentrations of, e.g., diclofenac,
ketoprofen, ranitidine, gemfibrozil, bezafibrate, pravastatin,
and ofloxacin were steadier than for the conventional
system. Occasionally removal efficiency was very similar,
and high, for both treatments (e.g. for ibuprofen, naproxen,
acetaminophen, paroxetine, and hydrochlorothiazide). The
antiepileptic drug carbamazepine was the most persistent
pharmaceutical and it passed through both the MBR and
CAS systems untransformed. Because there was no
washout of biomass from the reactor, high-quality effluent
in terms of chemical oxygen demand (COD), ammonium
content (N-NH4), total suspended solids (TSS), and total
organic carbon (TOC) was obtained.
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Introduction
Most pharmaceutical substances are, by nature, biologically
active and hydrophilic, in order that the human body can
take them up easily, and persistent, to avoid degradation
before they have a curing effect. Depending on the
pharmacology of a medical substance it will be excreted
as a mixture of metabolites, as unchanged substance, or
conjugated with an inactivating compound attached to the
molecule [1]. When they enter a wastewater-treatment
plant, xenobiotics are not usually completely mineralized.
They are either partially retained in the sludge, or
metabolized to a more hydrophilic but still persistent form
and, therefore, pass through the wastewater-treatment plant
(WWTP) and end up in the receiving waters. Their removal
in WWTPs is variable and depends on the properties of the
substance and process conditions (e.g. sludge retention time
(SRT), hydraulic retention time (HRT), temperature) [2, 3].
Levels of many pharmaceutically active compounds
(PhACs) are barely reduced and they are, therefore,
detected in WWTP effluents. The presence of PhACs in
surface, drinking, and wastewaters is well documented in
the literature [1, 4–12]. Although present at low concen-
trations in the environment, drugs can have adverse effects
on aquatic organisms. These effects are chronic rather than
acutely toxic, and depend on exposure (bioavailability),
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To ensure compliance with future discharge require-
ments, upgrading of existing wastewater-treatment facilities
and implementation of new technologies is envisaged as the
next step in improvement of wastewater treatment. In the
last ten to fifteen years the use of membranes in wastewater
reclamation has attracted much interest. Membrane tech-
nology has become a technically and economically feasible
alternative for water and wastewater treatment, especially
because of high SRTs achieved within compact reactor
volumes. In the MBR the concentration of microorganisms
can be increased to up to 20 mg L
−1. Because of this high
biomass concentration the rate of degradation is higher and
specialists are grown for problematic compounds. Another
advantage of membrane treatment is separation of sus-
pended solids by membranes, so they are not limited by the
settling characteristics of the sludge. The performance, in
terms of effluent quality, is believed to be better, but there is
a striking lack of knowledge about the behaviour of trace-
pollutants. Literature data on this subject is still very limited
and contradictory [2, 11, 14–16]. Ultrafiltration membranes
do not enable greater retention of the drugs investigated in
this study as a result of filtration effects—the molecular
sizes of the compounds selected are at least a factor of 100
smaller than the pore size of the membranes. Additional
removal of hydrophobic compounds by membranes can,
nevertheless, be expected, because they are adsorbed by
particles deposited as a layer on the membrane surface; this
effect for hydrophilic compounds is not yet very well
defined, however [11, 17].
The objectives of this work were detection of target
pharmaceuticals in wastewater influents and effluents,
observation of their elimination in the CAS process, and
comparison with results obtained for a laboratory-scale
MBR provided with a plate-and-frame submerged mem-
brane module. The pharmaceutical products investigated
were analgesics and anti-inflammatory drugs (ibuprofen,
ketoprofen, naproxen, diclofenac, indomethacin, acetamin-
ophen, mefenamic acid, and propyphenazone), lipid regu-
lators and cholesterol-lowering statin drugs (clofibric acid,
gemfibrozil, bezafibrate, pravastatin, and mevastatin), anti-
biotics (erythromycin, azithromycin, sulfamethoxazole,
trimethoprim, and ofloxacin), psychiatric drugs (fluoxetine
and paroxetine), an antiepileptic drug (carbamazepine), β-
blockers (atenolol, sotalol, metoprolol, and propranolol),
anti-histaminics (famotidine and loratidine), anti-ulcer
agents (lansoprazole and ranitidine), an anti-diabetic
(glibenclamide), and a diuretic (hydrochlorothiazide).
These compounds had different physicochemical properties
(i.e. neutral, ionic, hydrophilic, hydrophobic). Their chem-
ical structures and CAS numbers are listed in the Appendix.
If their behaviour during wastewater treatment could be
more reliably related to process design and operating
conditions, process performance could possibly be im-
proved by alteration of these conditions in accordance with
the types of molecule that are difficult to eliminate.
Experimental
Materials and standards
Chemical standards of carbamazepine, lansoprazole, lorati-
dine, famotidine, trimethoprim, ofloxacin, atenolol, meto-
prolol, azithromycin dihydrate, erythromycin hydrate,
fluoxetine hydrochloride, ranitidine hydrochloride, sulfa-
methoxazole, propranolol hydrochloride, indomethacin,
acetaminophen, mefenamic acid, clofibric acid, bezafibrate,
mevastatin, and sotalol hydrochloride were purchased from
Sigma–Aldrich (Steinheim, Germany), propyphenazone,
pravastatin, and paroxetine hydrochloride from LGC
Promochem (London, UK), ketoprofen, diclofenac, gemfi-
brozil, ibuprofen, and naproxen from Jescuder (Rubí,
Spain), glibenclamide from SIFA Chemicals (Liestal,
Switzerland), and hydrochlorothiazide from Pliva (Zagreb,
Croatia). All pharmaceutical standards were of high-purity
grade (>90%).
Isotopically labelled compounds used as internal stan-
dards were
13C-Phenacetin, from Sigma–Aldrich, meco-
prop-d3, from Dr Ehrenstorfer (Augsburg, Germany), and
ibuprofen-d3, atenolol-d7, and carbamazepine-d10 from
CDN Isotopes (Quebec, Canada).
All solvents (methanol, acetonitrile, and water) were
HPLC-grade and were purchased from Merck (Darmstadt,
Germany), as also was hydrochloric acid (HCl, 37%),
ammonium acetate (NH4Ac), and acetic acid (HAc).
Nitrogen for drying, purity 99.995%, was from Air Liquide
(Spain).
Stock solutions of individual standards (1 g L
−1)a n d
internal standards were prepared in methanol and stored at
−20 °C. Stock solutions of ofloxacin, pravastatin, and
sulfamethoxazole were renewed monthly because of their
limited stability. A standard mixture in which the compounds
were at a concentration of approx. 20 mg L
−1 was prepared
from the stock solutions. Further dilutions of this mixture
were prepared in 25:75 (v/v)m e t h a n o l –water and were used
as working standard solutions. A mixture of internal stan-
dards prepared by dilution of individual stock solutions in
methanol was used for internal standard calibration.
Membrane bioreactor (MBR)
A submerged MBR of approximately 21 L active volume
equipped with two flat sheet membranes (A4 size, area
0.106 m
2, pore size 0.4 μm), purchased from Kubota
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Rubí (Barcelona, Spain). Although the nominal porosity of
the membranes was 0.4 μm (microfiltration) a fouling layer
of proteins and microorganisms formed on the surface of
the membranes reduced the effective porosity to 0.01 μm,
which brought the type of filtration into the ultrafiltration
range [17].
The MBR was operated in parallel with the CAS process
(aeration tank and secondary settling tank). The biocenosis
of the MBR was grown from inoculated sludge from the
municipal WWTP (aeration basin) and cultivated over a
period of approximately 1 month to reach steady-state
conditions. The hydraulic retention time was set to 14 h by
regulating the effluent flow and the SRT was infinite,
because no sludge was discharged from the reactor.
The laboratory-scale MBR was operated dynamically in
intermittent permeation mode—cycles of permeation for
8 min interrupted with 2 min of halt. Influent and permeate
flows were controlled by use of flow meters and computer-
controlled pumps. Continuous aeration was provided by
means of a sparger pipe situated at the bottom of the
reaction vessel; the oxygen concentration was kept between
1 and 2 mg L
−1. The temperature inside the reactor was
20±2 °C throughout sampling.
Wastewater-treatment plant (WWTP)
Rubí WWTP was designed for 125,550 inhabitant equiv-
alents. During the sampling programme the WWTP was
operating with an average daily flow of 22,000 m
3 day
−1.A
mixture of municipal, hospital, and industrial wastewater is
treated. Treatment consists of pretreatment, preliminary
treatment, primary sedimentation, and secondary (biologi-
cal) treatment. Pretreated wastewater goes through a
physical process of settling in a primary clarifier. Secondary
treatment occurs in pre-denitrification (anaerobic) and
nitrification (aerobic) tanks, and two secondary clarifiers.
Secondary sludge is recirculated to a primary clarifier
which improves the settling characteristics of the primary
sludge and increases sludge age. A mixture of primary and
secondary (activated) sludge is processed (thickening,
dewatering) and anaerobically digested, and biogas pro-
duced is used to heat a digester. The hydraulic retention
time of CAS treatment in WWTP Rubí, calculated for the
average daily flow, is approximately 12 h. During the
sampling programme the plant was operating with an SRTof
approximately 3 days. WWTP effluent is discharged into the
river Riera de Rubí, which flows into the Mediterranean sea.
Sampling and sample preparation
Sampling was conducted during May and June, 2005.
Twenty-eight samples were analyzed. All wastewater
samples were taken as time-proportional grab-samples,
bearing in mind the HRT of the MBR and CAS processes.
The sampling points were:
1. primary sedimentation tank effluent, as the inflow to
the conventional treatment plant and membrane
bioreactor,
2. CAS effluent, and
3. MBR effluent.
Wastewater samples were collected, in amber glass
bottles pre-rinsed with ultra-pure water, as 24-h composite
samples; the volume depended on the type of sample
(100 mL for influent wastewater and 200 mL for effluent).
Immediately on arrival at the laboratory they were filtered
through 1-μm glass fibre filters and then through 0.45 μm
Nylon membrane filters from Whatman (UK). The target
compounds were extracted in one step, by a method
described elsewhere [18], using a Baker vacuum system
(J.T. Baker, The Netherlands) and Waters (Milford, MA,
USA) Oasis HLB cartridges (60 mg, 3 mL) previously
conditioned at neutral pH with 5 mL methanol then 5 mL
Table 1 MRM transitions of the compounds analyzed
Compound MRM 1 MRM 2 MRM 3
Ibuprofen 205→161
Ketoprofen 253→209 253→197
Naproxen 229→170 229→185
Diclofenac 294→250 294→214
Indomethacin 356→297 356→255
Acetaminophen 152→110 152→93
Mefenamic acid 240→196 240→180
Propyphenazone 231→201 231→189
Clofibric acid 213→127 213→85
Gemfibrozil 249→121
Bezafibrate 360→274 360→154
Pravastatin 447→327
Mevastatin 391→185 391→159
Carbamazepine 237→194 237→192
Fluoxetine 310→44 310→148
Paroxetine 330→192 330→123
Lansoprazole 370→252 370→205
Famotidine 338→189 338→259
Ranitidine 315→176 315→130
Loratidine 383→337 383→267 383→259
Erythromycin 734.5→158 734.5→576.4
Azithromycin 749.5→591.4 749.5→158
Sulfamethoxazole 254→92 254→156
Trimethoprim 291→230 291→261
Ofloxacin 362→316
Atenolol 267→190 267→145
Sotalol 273→255 273→213
Metoprolol 268→133 268→159
Propranolol 260→166 260→183
Hydrochlorothiazide 296→269 296→205
Glibenclamide 494→369
Anal Bioanal Chem (2007) 387:1365–1377 1367deionised water (HPLC grade). Elution was performed
twice with 4 mL methanol at a flow of 1 mL min
−1. The
extracts were then evaporated under a nitrogen stream and
reconstituted with 1 mL 25:75 (v/v) methanol–water.
Chemical analysis
LC analysis was performed with a Waters (Milford, MA,
USA) 2690 HPLC system coupled to a Micromass Quattro
(Manchester, UK) triple quadrupole mass spectrometer
equipped with a Z-spray electrospray interface. Chromato-
graphic separation was achieved on a Purospher Star RP-18
endcapped column (125 mm×2.0 mm, particle size 5 μm)
and a C18 guard column, both from Merck.
A specific multi-residue analytical method was set up for
measurement of the concentrations of the pharmaceutical
compounds in wastewaters [18]. Analysis was performed in
multiple-reaction-monitoring (MRM) mode, in both posi-
tive and negative electrospray-ionization mode. This meth-
od was refined for analysis of hydrochlorothiazide and
glibenclamide. MRM transitions selected for each com-
pound are summarized in Table 1. In accordance with the
performance characteristics defined in EU Commission
Decision 2002/657/EC for confirmation and identification
of pharmaceuticals when using LC–tandem MS as the
instrumental technique, a minimum of three identification
points are required. When using LC–MS–MS (QqQ)
analysis two MRM transitions are sufficient to confirm
the identity of a compound. The MRM ratio, calculated as
the relationship between the abundances of both transitions
and the LC retention time are also criteria used to confirm
the presence of an analyte in the samples. In this study,
therefore, transitions between a precursor ion and the two
most abundant fragment ions were chosen for each analyte
when working in MRM mode, resulting in four identifica-
tion points, enough to conform with the aforementioned EU
Table 2 Mean recoveries of the selected compounds and method detection limits (MDL) in ng L
−1
Compound Recovery (%) MDL (ng L
−1)
Influent MBR effluent CAS effluent Influent MBR and CAS effluent
Ibuprofen 131 (18.1)
a 68.8 (11.0) 90.4 (11.0) 98.0 20.0
Ketoprofen 62.8 (2.94) 71.3 (3.11) 59.1 (0.897) 190 74.0
Naproxen 49.2 (20.0) 59.4 (1.28) 53.4 (2.31) 79.0 20.0
Diclofenac 83.3 (1.17) 94.9 (10.0) 95.0 (12.6) 160 40.0
Indomethacin 113 (2.95) 120 (5.63) 110 (3.78) 150 31.0
Acetaminophen 123 (17.0) 108 (10.5) 56.0 (7.61) 20.9 5.35
Mefenamic acid 93.3 (1.95) 92.1 (1.02) 91.5 (5.29) 5.70 1.85
Propyphenazone 60.0 (8.00) 71.0 (4.00) 71.0 (4.00) 4.80 1.45
Clofibric acid 86.0 (10.8) 104 (6.87) 74.5 (1.40) 16.3 3.75
Gemfibrozil 91.0 (8.47) 87.5 (1.36) 108 (17.2) 8.70 2.20
Bezafibrate 106 (3.43) 94.4 (9.30) 89.4 (4.62) 18.5 4.35
Pravastatin 85.6 (2.56) 78.0 (12.2) 96.0 (19.5) 120 30.9
Mevastatin 103 (8.61) 134 (15.6) 123 (9.86) 9.30 1.30
Carbamazepine 84.0 (7.84) 89.5 (5.20) 88.0 (9.24) 2.20 0.600
Fluoxetine 46.7 (2.34) 93.7 (17.6) 59.0 (1.60) 19.8 1.70
Paroxetine 62.2 (2.15) 109 (5.73) 71.4 (1.49) 3.50 0.650
Lansoprazole 70.0 (10.0) 87.0 (5.00) 86.0 (4.00) 10.9 4.20
Famotidine 58.2 (7.76) 55.4 (6.30) 66.6 (5.39) 3.10 0.40
Ranitidine 41.5 (9.85) 75.8 (14.8) 125 (11.7) 1.40 0.300
Loratidine 72.6 (1.81) 78.0 (6.97) 64.5 (4.98) 8.00 2.75
Erythromycin 67.7 (3.15) 50.0 (13.0) 66.6 (12.0) 12.4 2.00
Azithromycin 30.0 (7.00) 73.0 (2.00) 63.0 (3.00) 1.00 0.300
Sulfamethoxazole 33.7 (2.76) 95.5 (9.24) 78.3 (1.08) 16.1 3.10
Trimethoprim 58.8 (3.29) 128 (6.58) 60.8 (3.87) 1.30 0.350
Ofloxacin 142 (19.0) 135 (5.45) 138 (4.47) 29.3 7.85
Atenolol 83.5 (33.8) 60.8 (10.8) 131 (15.5) 1.70 0.750
Sotalol 47.1 (2.91) 31.9 (3.05) 52.0 (3.63) 4.80 0.700
Metoprolol 36.7 (1.44) 120 (2.64) 76.7 (1.43) 6.30 1.60
Propranolol 60.2 (0.506) 90.8 (4.02) 70.5 (5.27) 2.60 0.300
Hydrochlorothiazide 39.8 (7.43) 58.9 (1.62) 73.4 (22.9) 4.50 0.900
Glibenclamide 100 (11.7) 107 (10.3) 98.5 (11.7) 19.2 2.30
aThe relative standard deviation (%) of the recoveries is given in parentheses (n=3)
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compounds, only one transition could be monitored.
Confirmation of the identities of these was achieved by
matching their LC retention times with those of standards.
Shifts in retention times were less than 3%, so the
confirmation was regarded as sufficiently reliable. For
internal standards only one transition was selected, because
they were isotopically labelled compounds unlikely to be
found in environmental samples.
To compensate for matrix effects from sample matrices
internal standard calibration and adequate dilution of
sample extracts were used, on the basis of the previously
published method [18].
Recoveries of the method were determined by spiking.
Influent samples and CAS and MBR effluents were spiked
in triplicate with a standard mixture of selected compounds
to a final concentration of 1 μgL
−1. Spiked samples and a
blank sample were analysed by the above mentioned
method. Recoveries of the target pharmaceuticals are listed
in Table 2, with method detection limits (MDL) for influent
and effluent samples. MDLs and method quantification
limits (MQL) were calculated on the basis of signal-to-
noise ratios (S/N) of 3 and 10, respectively.
Results and discussion
It is well documented that WWTPs are major contributors
of pharmaceuticals in the environment. WWTP Rubí
mainly receives domestic, hospital, and industrial wastewa-
ter and effluent concentrations of several monitored com-
pounds exceed μgL
−1 levels. Ranges of output loads for
WWTP Rubi for each pharmaceutical and mean values
(g day
−1)a r er e p o r t e di nT a b l e3. The quantities of
pharmaceuticals discharged into the environment are
calculated by multiplying the detected effluent concentra-
tions by an average daily flow rate of 22,000 m
3 day
−1. The
total amount of pharmaceutical compounds discharged by
WWTP Rubi into the environment exceeded 300 g day
−1
(an average value). The most abundant compounds, with
average individual loads of 21–56 g day
−1, were the anti-
inflammatory drugs ibuprofen, naproxen, and diclofenac,
the lipid regulators gemfibrozil and bezafibrate, the diuretic
hydrochlorothiazide, and the β-blocker atenolol.
To assess the efficiency of elimination by the MBR,
substance-specific analysis must be performed and the bulk
properties DOC and COD of wastewater influents and
effluents must also be determined. The performance of the
MBR system is summarized in Table 4. The data are
presented for the sampling period. Removal efficiencies of
98.7% for TSS and 90.4% for total COD were achieved
during the membrane process. Average effluent ammonia
concentration was 1.01 μgL
−1 in the MBR effluent, com-
pared with 48.41 μgL
−1 in the CAS effluent. It is known
that membrane processes are quite efficient at removing
COD and TOC from wastewater [19, 20]. Improved COD
removal is attributed to the combination of complete
retention of particulate material by the membrane, including
suspended COD and high molecular weight organisms, and
to avoidance of biomass washout problems common in
activated sludge systems. Consequently, stable conditions
are provided for growth of specialized microorganisms
which are the able to remove poorly biodegradable
components.
Of 31 pharmaceutical products included in the analytical
method, 22 were detected in the wastewater entering
WWTP Rubí. Box plots of measured concentrations of
each pharmaceutical are showed in Figs. 1, 2 and 3.T e n
measured values are given for influent and MBR effluent
concentrations and eight for CAS effluent (data are missing
Table 3 Average daily output loads of the investigated pharmaceu-
ticals for Rubí WWTP
Pharmaceutical Effluent load (g day
−1)
Mean Range
Analgesics and anti-inflammatory drugs
Naproxen 37.0 10.8–76.9
Ketoprofen 17.1 11.4–36.3
Ibuprofen 56.3 7.39–137.9
Diclofenac 27.3 17.3–43.8
Indomethacin 1.93 nd–2.73
Acetaminophen 4.55 1.06–9.2
Mefenamic acid 0.44 0.27–0.85
Propyphenazone 0.68 0.43–0.96
Anti-ulcer agent
Ranitidine 2.77 0.55-5.30
Psychiatric drug
Paroxetine 0.08 nd
a–0.16
Antiepileptic drug
Carbamazepine 5.21 1.44-6.71
Antibiotics
Ofloxacin 6.93 2.40–11.2
Sulfamethoxazole 3.06 1.42–5.81
Erythromycin 2.29 0.95–4.51
β-blockers
Atenolol 21.0 7.70–33.2
Metoprolol 3.32 1.14–5.43
Diuretic
Hydrochlorothiazide 33.7 21.2–46.0
Hypoglycaemic agent
Glibenclamide 0.74 nd–0.98
Lipid regulator and cholesterol lowering statin drugs
Gemfibrozil 54.3 30.1–73.9
Bezafibrate 21.6 10.9–50.8
Clofibric acid 1.75 0.40–3.43
Pravastatin nd nd
aNot detectable (below the LOQ)
Anal Bioanal Chem (2007) 387:1365–1377 1369for two sampling programmes). For each variable the box
has lines at the lower quartile (25%), median (50%), and
upper quartile (75%) values. The whiskers are the lines
extending from each end of the box to show the extent of
the data up to 1.5 times the interquartile range (IQR).
Outliers are marked with + symbols.
The highest influent concentrations (μgL
−1)w e r e
measured for the analgesics and anti-inflammatory drugs
naproxen, ibuprofen, ketoprofen, diclofenac, and acetamin-
ophen, the antihyperlipoproteinaemic drugs gemfibrozil and
bezafibrate, the β-blocker atenolol, and the diuretic
hydrochlorothiazide. For other compounds input concen-
trations were usually in the range 10–100 ng L
−1. Because
the low concentrations measured were sometimes close to
the limits of quantification, any hypothesis about the
efficiency of their elimination is questionable. Mean
removal was, nevertheless, calculated for each of the
pharmaceutical compounds; the results are presented in
Table 5. The most important removal pathways of organic
compounds during wastewater treatment are:
1. biotransformation/biodegradation,
2. adsorption by the sludge (excess sludge removal), and
3. stripping by aeration (volatilization).
Because of the low values of the Henry coefficients (KH)
of the compounds investigated [21], the fraction removed
by volatilization can be neglected [16]. The two processes
abiotic (adsorption) and biotic degradation (transformation
by microorganisms) could not be distinguished, because no
method was developed for analysis of the target compounds
in sludge. The term “removal” is therefore used here for
conversion of a micropollutant to compounds other than the
parent compound.
Elimination efficiency of the laboratory-scale MBR and
the full-scale CAS process was comparable for naproxen,
ibuprofen, acetaminophen, hydrochlorothiazide, and parox-
etine. All were removed to a large extent by both systems
(removal was greater than 80% except for hydrochlorothi-
azide, for which it was between 56 and 85%). Hydrochlo-
rothiazide and paroxetine were eliminated slightly better by
conventional treatment. Similar results for the behaviour of
these drugs during conventional treatment have been
reported by several authors [2, 3, 9, 11].
For ketoprofen, diclofenac, bezafibrate, and gemfibrozil
removal by the MBR system was very high and uniform
(>90%), with the exception of two sampling programme. It
is assumed this variation could have been a result of
reduced microbial activity or altered sorption and floccula-
tion conditions. No plausible explanation can be given for
the drastically reduced efficiency of removal of clofibric
and mefenamic acid by MBR in two sampling programmes;
otherwise these were eliminated with efficiencies between
65 and 90%. High and steady removal (>80%) in the MBR
was also observed for ranitidine and ofloxacin. In conven-
tional treatment all these pharmaceuticals were eliminated
with a wide range of efficiencies, always lower than those
obtained by the MBR. Better removal of readily biode-
gradable micropollutants by the MBR could be because of
the smaller flock size of the sludge, which enhances mass
transfer by diffusion and therefore increases elimination.
Taking into consideration the composition of sludge
originating from a membrane bioreactor (specialized micro-
organisms, large amount of active biomass in suspended
solids) improved removal is to be expected; this was
confirmed by our experiments.
A possible explanation of substantially greater attenua-
tion of diclofenac by the MBR (average removal efficiency
87% compared with 50% in CAS) could be the greater age
of the MBR sludge. Improved removal is observed with
increasing solids retention time [14]. Another explanation
could be greater adsorption potential of the MBR sludge,
because the organic matter content is greater than for CAS
sludge. According to results from the EU project Poseidon
[22], adsorption processes affect elimination of diclofenac.
Literature data on this matter is still very contradictory.
Clara et al. reported poor removal of diclofenac in
laboratory-scale WWTPs whereas in full-scale plants
removal varied from less than 20% to between 60 and
80% for some of the facilities investigated [2]. Heberer et
al. [7] reported low removal efficiencies in a WWTP
whereas Ternes et al. documented significant (69%)
elimination of diclofenac [8].
Removal of carbamazepine was, in contrast, very poor
(<20%), and effluent concentrations for both MBR and
CAS were frequently greater than influent levels. Poor
elimination of this neutral drug has been reported by many
authors [9, 11, 23, 24]. Glucuronide conjugates of carba-
Table 4 Summary of the per-
formance of the MBR system
aValues are averages from
n=16 samples, with standard
deviations in parentheses
Property Influent MBR effluent CAS effluent
TSS (mg L
−1) 119.2 (17.37)
a 1.600 (1.770) 26.72 (15.69)
CODtotal (mg L
−1) 508.2 (124.3) 48.58 (22.47) 111.6 (53.35)
TOC (mg L
−1) 67.67 (24.29) 10.89 (3.470) 27.33 (13.75)
N-NH4 (mg L
−1) 49.13 (15.79) 1.010 (0.4200) 48.41 (12.87)
pH 7.52 (0.300) 7.08 (0.270) 7.63 (0.160)
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Fig. 1 Removal, during MBR and CAS treatment, of the analgesics and anti-inflammatory drugs naproxen (a), ketoprofen (b), ibuprofen (c),
mefenamic acid (d), diclofenac (e), indomethacin (f), acetaminophen (g), and propyphenazone (h)
Anal Bioanal Chem (2007) 387:1365–1377 13710
200
400
600
800
1000
1200
OFLOXACIN
influent         MBR effluent    CAS effluent
0
200
400
600
800
1000
1200
0
200
400
600
800
1000
1200
OFLOXACIN
influent         MBR effluent    CAS effluent influent         MBR effluent    CAS effluent
a)
200
400
600
800
1000
1200
SULFAMETHOXAZOLE
influent MBR effluent           CAS effluent 
b)
200
400
600
800
1000
1200
200
400
600
800
1000
1200
SULFAMETHOXAZOLE
influent MBR effluent           CAS effluent 
0
1
2
3
4
5
ATENOLOL
influent         MBR effluent    CAS effluent
d)
0
1
2
3
4
5
0
1
2
3
4
5
ATENOLOL
influent         MBR effluent    CAS effluent influent         MBR effluent    CAS effluent
0
500
1000
1500
2000
2500
3000
3500
4000
4500
METOPROLOL
influent         MBR effluent    CAS effluent
e)
0
500
1000
1500
2000
2500
3000
3500
4000
4500
0
500
1000
1500
2000
2500
3000
3500
4000
4500
METOPROLOL
influent         MBR effluent    CAS effluent
0
100
200
300
400
500
600
700
800
RANITIDINE
influent         MBR effluent    CAS effluent
f)
0
100
200
300
400
500
600
700
800
0
100
200
300
400
500
600
700
800
RANITIDINE
influent         MBR effluent    CAS effluent
100
200
300
400
500
600
CARBAMAZEPINE
influent         MBR effluent    CAS effluent
g)
100
200
300
400
500
600
100
200
300
400
500
600
CARBAMAZEPINE
influent         MBR effluent    CAS effluent influent         MBR effluent    CAS effluent
0
10
20
30
40
50
60
PAROXETINE
influent         MBR effluent    CAS effluent
h)
0
10
20
30
40
50
60
0
10
20
30
40
50
60
PAROXETINE
influent         MBR effluent    CAS effluent
0
50
100
150
200
250
ERYTHROMYCIN
influent MBR effluent           CAS effluent
c)
0
50
100
150
200
250
0
50
100
150
200
250
ERYTHROMYCIN
influent MBR effluent           CAS effluent influent MBR effluent           CAS effluent
c
 
(
n
g
/
L
)
c
 
(
n
g
/
L
)
c
 
(
n
g
/
L
)
c
 
(
n
g
/
L
)
c
 
(
n
g
/
L
)
c
 
(
n
g
/
L
)
c
 
(
µ
g
/
L
)
c
 
(
n
g
/
L
)
1372 Anal Bioanal Chem (2007) 387:1365–1377mazepine can, presumably, be cleaved in sewage, thus
increasing environmental concentrations [8].
Rates of removal of the antibiotic sulfamethoxazole were
very variable in both treatments investigated. According to
Drillia et al. its microbial degradation will depend on the
presence of readily biodegradable organic matter in
wastewater; this varies during both MBR and CAS
treatment [25]. Also, a substantial amount of sulfamethox-
azole enters WWTPs as its human metabolite N4-acetylsul-
famethoxazole, which can possibly be converted back to
the original compound during treatment [26].
Efficiency of removal of atenolol, metoprolol, pravastatin,
erythromycin, and indomethacin varied in both MBR and
CAS treatment. This could not be explained. Fluctuation of
elimination efficiency was also observed for propyphenazone
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Fig. 3 Removal during MBR and CAS treatment of the lipid regulator and cholesterol-lowering statin drugs gemfibrozil (a), bezafibrate (b),
clofibric acid (c), and pravastatin (d), the diuretic hydrochlorothiazide (e), and the hypoglycaemic agent glibenclamide (f)
Fig. 2 Removal during MBR and CAS treatment of the antibiotics
ofloxacin (a), sulfamethoxazole (b), and erythromycin (c), the β-
blockers atenolol (d) and metoprolol (e), the anti-ulcer agent ranitidine
(f), the antiepileptic drug carbamazepine (g), and the psychiatric drug
paroxetine (h)

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glibenclamide (14.8–73.7% for MBR and 11.9–79.7% for
CAS).
Effluent concentrations greater than those recorded for
the influent could be explained by the presence of input
conjugate compounds that are transformed into the original
compounds during treatment. Because these conjugates
were not included in the analysis, no firm conclusion can be
made about their biotransformation, especially because
sampling inaccuracy can also lead to errors.
Conclusion
Several pharmaceutical products (e.g. ibuprofen, naproxen,
acetaminophen, ketoprofen, diclofenac, bezafibrate, gemfi-
brozil, ranitidine, ofloxacin, hydrochlorothiazide, and parox-
etine) with high rates of attenuation can be expected to be
completely removed from wastewater by adsorption or
degradation, or a combination of both, during membrane
treatment. For most of the compounds investigated MBR
effluent concentrations were significantly lower than in the
effluent from conventional treatment. Elimination of hydro-
chlorothiazide and paroxetine was slightly better in CAS
treatment. Some substances (e.g. carbamazepine) were not
removed by either MBR or CAS treatment. No relationship
was found between the structures of target compounds and
their removal during wastewater treatment, however. The
range of variation of the efficiency of removal by the MBR
system was small for most of the compounds; in conven-
tional treatment greater fluctuations were observed and
removal efficiency was found to be much more sensitive to
changes in operating conditions (temperature, flow rate, etc).
Although membrane technology seems a promising
means of removal of pharmaceutical compounds, the
MBR process investigated would not completely halt
discharge of micropollutants. Membrane treatment process-
es should be optimized by modification of the membranes
(variation of the materials and reduction of molecular mass
cut-off limits) and/or by modification of the treatment
process (inoculation of special microorganisms). The
efficiencies of diverse microbial populations in elimination
of selected pharmaceuticals, and optimization of design and
operating conditions of a laboratory-scale MBR will be the
main objectives of our future investigations. That would
provide guidelines for scale-up of a biological pilot plant
and its evaluation by integration into an industrial process
water-recycling system. Because of the current lack of
information on the behaviour of pharmaceuticals in surface
and wastewaters, however, further studies are required on
the occurrence, fate, and effects of these substances in the
environment.
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Appendix
Structure and CAS numbers of the pharmaceutical products
studied.
Table 5 Mean removal of selected pharmaceuticals by the MBR and
CAS processes
Compound Elimination (%) in:
MBR
a CAS
b
Analgesics and anti-inflammatory drugs
Naproxen 99.3 (1.52) 85.1 (11.4)
Ketoprofen 91.9 (6.55) 51.5 (22.9)
Ibuprofen 99.8 (0.386) 82.5 (15.8)
Diclofenac 87.4 (14.1) 50.1 (20.1)
Indomethacin 46.6 (23.2) 23.4 (22.3)
Acetaminophen 99.6 (0.299) 98.4 (1.72)
Mefenamic acid 74.8 (20.1) 29.4 (32.3)
Propyphenazone 64.6 (13.3) 42.7 (19.0)
Anti-ulcer agents
Ranitidine 95.0 (3.74) 42.2 (47.0)
Psychiatric drugs
Paroxetine 89.7 (6.69) 90.6 (4.74)
Antiepileptic drugs
Carbamazepine No elimination
c No elimination
Antibiotics
Ofloxacin 94.0 (6.51) 23.8 (23.5)
Sulfamethoxazole 60.5 (33.9) 55.6 (35.4)
Erythromycin 67.3 (16.1) 23.8 (29.2)
B-blockers
Atenolol 65.5 (36.2) No elimination
Metoprolol 58.7 (72.8) No elimination
Diuretics
Hydrochlorothiazide 66.3 (7.79) 76.3 (6.85)
Hypoglycaemic agents
Glibenclamide 47.3 (20.1) 44.5 (19.1)
Lipid regulator and cholesterol lowering statin drugs
Gemfibrozil 89.6 (23.3) 38.8 (16.9)
Bezafibrate 95.8 (8.66) 48.4 (33.8)
Clofibric acid 71.8 (30.9) 27.7 (46.9)
Pravastatin 90.8 (13.2) 61.8 (23.6)
a,bValues are averages, with relative standard deviations (%) in
parentheses, for n=10
a or n=8
b samples
cCompounds were classified as “no elimination” if elimination was
less than 10%
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